-
B608219-25mgbrincidofovir.
-
B608219-5mgbrincidofovir.
-
B127317-100mgBrivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.
-
B127317-10mgBrivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.
-
B127317-50mgBrivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.
-
B127317-5mgBrivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.
-
B129764-10mgBrivanib Alaninate (BMS-582664).
-
B129764-50mgBrivanib Alaninate (BMS-582664).
-
-
-
B335093-10mgBRL 44408 maleate is a selective α2A-AR antagonist. Adrenoreceptors, or adrenergic receptors are G protein-coupled proteins involved in a variety of sympathetic activities. In general, α2A-AR has been associated with regulation of neurotransmitter
-
B335093-5mgBRL 44408 maleate is a selective α2A-AR antagonist. Adrenoreceptors, or adrenergic receptors are G protein-coupled proteins involved in a variety of sympathetic activities. In general, α2A-AR has been associated with regulation of neurotransmitter